DRD2 and Parkinson disease: The use of water soluble β-1 adrenergic blocking agents that poorly cross the blood brain barrier and exhibit no intrinsic sympathomimetic activity might reduce the CV morbidity and mortality without exerting CNS side effects among PD patients on long-term D2R agonist therapy.